http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 06:59:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS